Dr. Garner is responsible for developing novel PK and PK/PD models to support discovery and development of small and large molecules. He has over 20 years of experience in PK and metabolism and has published numerous publications in pharmacokinetics and toxicokinetics of small molecules, human pharmacokinetic estimation, pharmacodynamics modeling, transporter interaction studies, metabolism, and P450 induction.
Dr. Garner’s previous tenure with three major pharmaceutical companies included direction of DMPK support in preclinical drug discovery and development projects, predominantly in anticancer, anti-inflammatory, and anti-infective compounds. He has led groups responsible for in vivo pharmacokinetics, physiologically based pharmacokinetic modeling, pharmacodynamic models and clinical dose estimations and efficacious regimen design of pharmaceuticals. His individual research was oriented towards development of PK/PD models to guide Phase I/II dose and regimen for several anti-cancer programs. He has experience in building multidiscipline research coalitions between industry and academic research programs in drug discovery in both domestic and international arenas. Dr. Garner received his Ph.D. in Toxicology from North Carolina State University. His doctoral research, conducted at the National Institute of Environmental Health Sciences (NIEHS), focused on the contribution of metabolism to the carcinogenicity of polychlorinated biphenyls.